Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Vodafone Business Services (VBS) collaborate with Diabetacare to launch dCare Smart, a device that helps people manage diabetes better. The device transmits blood sugar results to a secure Diabetacare server, where they are constantly monitored by diabetes specialist clinicians at the Diabetacare’s Diabetes Management Centre (DMC). dCare Smart is paired with the back-end clinical servers which connect directly to the electronic medical record system, wherein access is given to patients and their caregivers to keep them informed and better manage the condition.

  • Biocon’s novel drug pipeline which has an ophthalmology molecule, QPI-1007, is entering clinical trial phase. QPI-1007 is for ocular neuroprotection in NAION and acute angle closure glaucoma. In mid-December 2013, the company entered into a licensing and collaboration agreement for the development of a range of siRNA (small interfering RNA) based novel therapeutics with Quark Pharmaceuticals which was researching on QPI-1007.

  • A team of scientists believe they have shown that memories are more robust than we thought and have identified the process in the brain, which could help rescue lost memories or bury bad memories, and pave the way for new drugs and treatment for people with memory problems.

  • The question of why we age is one of the most fascinating questions for humankind, but nothing close to a satisfactory answer has been found to date. Scientists at the Leibniz-Institut für Molekulare Pharmakologie in Berlin have now taken one step closer to providing an answer.

  • USFDA rejected Sun Pharma Advanced Research Company’s Application for its new anti-glaucoma eye drops. The product is to be manufactured at Sun Pharmaceutical Industries’ Halol facility. USFDA has indicated that a satisfactory resolution of the current good manufacturing practice (cGMP) deficiencies at this facility is a prerequisite for the final approval of Xelpros.

Subscribe to Pharma News